Phase I trial of continuous infusion flavopiridol, a novel cyclin- dependent kinase inhibitor, in patients with refractory neoplasms

Journal of Clinical Oncology

Volumn 16, Issue 9, 1998, Pages 2986-2999

  Senderowicz, Adrian M ^a   Headlee, Donna ^b   Stinson, Sherman F ^b   Lush, Richard M ^b   Kalil, Nelson ^b   Villalba, Lourdes ^b   Hill, Kimberly ^b   Steinberg, Seth M ^b   Figg, William D ^b   Tompkins, Anne ^b   Arbuck, Susan G ^b   Sausville, Edward A ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; FLAVOPIRIDOL;

ADULT; AGED; ARTICLE; CANCER; CANCER CHEMOTHERAPY; CANCER PAIN; CLINICAL TRIAL; COLON CANCER; CONTINUOUS INFUSION; DIARRHEA; DRUG BLOOD LEVEL; DRUG RESPONSE; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOTENSION; INFLAMMATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CANCER; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 0031670668     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.9.2986     Document Type: Article

References (42)

1. Bailar JC III, Gornik HL: Cancer undefeated. N Engl J Med 336:1569-1574, 1997
2. Monks A, Scudiero D, Johnson G, et al: The NCI anti-cancer drug screen: A smart screen to identify effectors of novel targets. Anticancer Drug Des 12:533-541, 1997
3. Hartwell LH, Kastan MB: Cell cycle control and cancer. Science 266:1821-1828, 1994
4. Harper J, Elledge S: CDK inhibitors in development and cancer. Curr Opin Genet Dev 6:56-64, 1996
5. Morgan DO: Principles of CDK regulation. Nature 374:131-134, 1995
6. Pines J: Cyclins and cyclin-dependent kinases: A biochemical view. Biochem J 308:697-711, 1995
7. Sherr CJ: Cancer cell cycles. Science 274:1672-1677, 1996
8. Cordon-Cardo C: Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol 147:545-560, 1995
9. Sausville EA, Senderowicz AM: Chemical cyclin-dependent kinase inhibitors: Therapeutic implications, in Gutkind JS (ed): Signal Transduction, Cell Cycle and Their Inhibitors. Totowa, NJ, The Humana Press, Inc, 1998 (in press)
10. Sedlacek HH, Czech J, Naik R, et al: Flavopiridol (L86-8275, NSC-649890), a new kinase inhibitor for tumor therapy. Int J Oncol 9:1143-1168, 1996
11. Kaur G, Stetler-Stevenson M, Sebers S, et al: Growth inhibition with reversible cell-cycle arrest of carcinoma cells by flavone L86-8275. J Natl Cancer Inst 84:1736-1740, 1992
12. Worland PJ, Kaur G, Stetler-Stevenson M, et al: Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Correlation with decreased H1 kinase activity. Biochem Pharmacol 46:1831-1840, 1993
13. Losiewicz MD, Carlson BA, Kaur G, et al: Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. Biochem Biophys Res Commun 201:589-595, 1994
14. Carlson BA, Dubay MM, Sausville EA, et al: Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res 56:2973-2978, 1996
15. De Azevedo WF Jr, Mueller-Dieckmann HJ, Schulze-Gahmen U, et al: Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc Natl Acad Sci U S A 93:2735-2740, 1996
16. Parker B, Kaur G, Nieves-Neira W, et al: Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood 91:458-465, 1998
17. Arguello F, Alexander M, Sterry J, et al: Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human and leukemia xenografts. Blood 91:2482-2490, 1998
18. Drees M, Dengler W, Roth T, et al: Flavopiridol (L86-8275): Selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells. Clin Cancer Res 32:273-279, 1997
19. Wittes R: Manual of Oncologic Therapeutics. Philadelphia, PA, Lippincott, 1991, p 445
20. Stinson S, Hill K, Siford T, et al: Determination of flavopiridol (L86-8275; NSC 649890) in human plasma by reversed-phase liquid chromatography with electrochemical detection. Cancer Chemother Pharmacol (in press)
21. Gibaldi M, Perrier D: Pharmacokinetics. New York, NY, Marcel Dekker, 1982
22. Hansen MB, Skadhauge E: New aspects of the pathophysiology and treatment of secretory diarrhea. Physiol Res 44:61-78, 1995
23. Abigerges D, Chabot GG, Armand JP, et al: Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every three weeks in cancer patients. J Clin Oncol 13:210-221, 1995
24. Shenfeld M, Senderowicz AM, Sausville EA, et al: A novel chemotherapeutic agent, flavopiridol, modulates intestinal epithelial chloride secretion. Gastroenterology 112:404, 1997 (abstr)
25. Harris AG, Odorisio TM, Woltering EA, et al: Consensus statement: Octreotide dose titration in secretory diarrhea. Diarrhea Management Consensus Development Panel. Dig Dis Sci 40:1464-1473, 1995
26. Rashid A, Hamilton SR: Necrosis of the gastrointestinal tract in uremic patients as a result of sodium polystyrene sulfonate (Kayexalate) in sorbitol: An underrecognized condition. Am J Surg Pathol 21:60-69, 1997
27. Kanda Y, Shigeno K, Kinoshita N, et al: Sudden hearing loss associated with interferon. Lancet 343:1134-1135, 1994
28. Roelofs RI, Hrushesky W, Rogin J, et al: Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology 34:934-938, 1984
29. Baumann H, Gauldie J: The acute phase response. Immunol Today 15:74-80, 1994
30. Bibby MC, Double JA, Phillips RM, et al: Flavone acetic acid: Is vascular shutdown the crucial mechanism of action? Int J Radiat Biol 60:395-399, 1991
31. Weiss RB, Greene RF, Knight RD, et al: Phase I and clinical pharmacology study of intravenous flavone acetic acid (NSC 347512). Cancer Res 48:5878-5882, 1988
32. Havlin KA, Kuhn JG, Craig JB, et al: Phase I clinical and pharmacokinetic trial of flavone acetic acid. J Natl Cancer Inst 83:124-128, 1991
33. Ferry RF, Smith A, Malkandi J, et al: Phase I clinical trial of the flavonoid quercetin: Pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res 2:659-668, 1996
34. Hoffmann J, Fiebig H, Winterhalter B, et al: Enhancement of the antiproliferative activity of cis-diaminedichloroplatinun (II) (CDDP) by quercetin. Int J Cancer 45:536-539, 1990
35. Fauci AS: Immunosuppressive and anti-inflammatory effects of glucocorticoids, in Baxler JD, Rousseau GG (eds): Glucocorticoid Hormone Action. New York, NY, Springer Verlag, 1979, pp 449-465
36. Boldt DH, Von Hoff DD, Kuhn JG, et al: Effects on human peripheral lymphocytes of in vivo administration of 9-β-D arabino furanosyl-2-fluoradenine 5′-monophosphate (NSC 312887), a new purine antimetabolite. Cancer Res 44:4661, 1984
37. Jager W, Zembsch B, Wolschann P, et al: Metabolism of the anticancer drug flavopiridol, a new inhibitor of cyclin dependent kinases, in rat liver. Life Sci 62:1861-1873, 1998
38. Supko J, Malspeis L: Plasma pharmacokinetics of genistein in mice. Int J Oncol 7:847-854, 1995
39. Lush R, Stinson S, Senderowicz A, et al: Flavopiridol pharmacokinetics suggest enterohepatic circulation. Clin Pharmacol Ther 61:145, 1997 (abstr)
40. Bible KC, Kaufmann SM: Flavopiridol: A cytotoxic flavone that induces cell death in non-cycling A549 lung carcinoma cells. Cancer Res 56:4856-4861, 1996
41. Bible KC, Kaufmann SM: Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: The importance of sequence of administration. Cancer Res 57:3375-3380, 1997
42. Schwartz GK, Farsi K, Maslak P, et al: Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells. Clin Cancer Res 3:1467-1472, 1997